Fam-Trastuzumab Deruxtecan-Nxki
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 71 publications
Discovery and Preclinical Evaluation of PBX-7016, a Methylenedioxy-Camptothecin Payload for Antibody-Drug Conjugates with Enhanced Therapeutic Potential.
Journal: Journal of medicinal chemistry
Published: December 19, 2025
Targeted Therapy in HER2 Exon 20-Mutant Non-small Cell Lung Cancer With Leptomeningeal Disease: A Case-Based Approach to Treatment Decision-Making.
Journal: Cureus
Published: July 28, 2025
Stabilization of Symptomatic Bone Marrow Metastases in Breast Cancer: A Case Report of Two Patients Treated With Trastuzumab Deruxtecan.
Journal: Cureus
Published: July 01, 2025
Fam-trastuzumab deruxtecan in a patient with metastatic human epidermal growth factor receptor 2-positive breast cancer and pre-existing cardiac failure: a case report.
Journal: AME case reports
Published: June 21, 2025
Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology.
Journal: International journal of molecular sciences
Published: June 11, 2025
Enhertu as an effective treatment for metastatic lung cancer with brain metastasis recurrence: a case report.
Journal: Annals of medicine and surgery (2012)
Published: May 24, 2025
Complete response to trastuzumab-deruxtecan (Enhertu, T-DXd) in HER2-positive stage IVB uterine carcinosarcoma.
Journal: Gynecologic oncology reports
Published: May 10, 2025
Elucidating Critical Factors of Internalization and Drug Release of Antibody-Drug Conjugates (ADCs) Using Kinetic Parameters Evaluated by a Novel Tool Named TORCH.
Journal: Bioconjugate chemistry
Published: May 06, 2025
Long Durable Response With Trastuzumab Deruxtecan Monotherapy in a Triple-Negative Metastatic Breast Cancer Patient With Human Epidermal Growth Factor Receptor 2 Mutation: A Long-Term Follow-Up and Literature Review.
Journal: Journal of medical cases
Published: April 29, 2025
HER2 mutation profiling in mucinous ovarian carcinoma: Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach.
Journal: Taiwanese journal of obstetrics & gynecology
Published: April 24, 2025
An Expedition of FDA-Approved Anticancer Drugs in 2024: Synthetic Routes, Mechanisms of Action, and Clinical Indications.
Journal: Current topics in medicinal chemistry
Published: April 15, 2025
Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies.
Journal: Chembiochem : a European journal of chemical biology
Published: April 11, 2025
Last Updated: 04/28/2026